SCHEMBL20567149

SCHEMBL20567149

CC(C)(C)OC(=O)c1n[nH]cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39
GABRA1 P14867 2/20 0.34
GABRG2 P18507 2/20 0.34
GABRB3 P28472 2/20 0.34
GABRA5 P31644 2/20 0.34
KMT2A Q03164 1/20 0.34
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRA6 Q16445 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ATR Q13535 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7421480 0.80 ALDH1A1 (0.41) LMNAALDH1A1CNR1CNR2GABRA1
SCHEMBL983024 0.79 NPSR1 (0.46) ALDH1A1KMT2ANPSR1
SCHEMBL27869406 0.79 ALDH1A1 (0.40) LMNAALDH1A1CNR1CNR2GABRA1
SCHEMBL38655809 0.77 ALDH1A1 (0.43) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL1633849 0.77 ALDH1A1 (0.40) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL21121082 0.76 ALDH1A1 (0.39) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL27667445 0.76 ALDH1A1 (0.39) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL8816833 0.76 ALDH1A1 (0.39) LMNAALDH1A1GABRA1GABRG2GABRB3
SCHEMBL983844 0.75 L3MBTL1 (0.48) ALDH1A1KMT2ANPSR1
SCHEMBL15701735 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12258340-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2025-03-25 US disclosed
CN-116473965-B Pyrazole MAGL inhibitors H.隆德贝克有限公司 2025-03-18 CN disclosed
CN-116473965-A Pyrazole MAGL inhibitors H.隆德贝克有限公司 2023-07-25 CN disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2023-07-13 US disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
EP-4198024-A1 PYRAZOLE MAGL INHIBITORS H. Lundbeck A/S (DK) 2023-06-21 EP disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
US-11655217-B2 Pyrazole MAGL inhibitors H. LUNDBECK A/S (DK) 2023-05-23 US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2021-02-25 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
US-10927105-B1 Pyrazole MAGL inhibitors LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) 2021-02-23 US disclosed
EP-3630744-A1 PYRAZOLE MAGL INHIBITORS Lundbeck La Jolla Research Center, Inc. (US) 2020-04-08 EP disclosed
CN-110678456-A Pyrazole MAGL inhibitors 隆德贝克拉荷亚研究中心有限公司 2020-01-10 CN disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
US-10266497-B2 Pyrazole MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2019-04-23 US disclosed
WO-2018217805-A1 PYRAZOLE MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-11-29 WO disclosed
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180339970-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL LMNA 2986/4885ALDH1A1 2448/4885CNR1 498/4885
US-20230219897-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL LMNA 2986/4885ALDH1A1 2448/4885CNR1 498/4885
US-12258340-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LMNA 3058/4885ALDH1A1 2260/4885CNR1 569/4885
US-10266497-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LMNA 2986/4885ALDH1A1 2448/4885CNR1 498/4885
US-20210053960-A1 PYRAZOLE MAGL INHIBITORS MGLL, PNLIP, LPL LMNA 2986/4885ALDH1A1 2448/4885CNR1 498/4885
US-11655217-B2 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LMNA 3058/4885ALDH1A1 2260/4885CNR1 569/4885
US-10927105-B1 Pyrazole MAGL inhibitors MGLL, PNLIP, LPL LMNA 2986/4885ALDH1A1 2448/4885CNR1 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.